Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial
Authors:
- Simona F. ShaitelmanSSSimona F. Shaitelman
- Xiudong LeiXLXiudong Lei
- Alastair ThompsonATAlastair Thompson
- Pamela SchlembachPSPamela Schlembach
- Elizabeth S. BloomEBElizabeth S. Bloom
- Isidora Y. ArzuIAIsidora Y. Arzu
- Daniel BuchholzDBDaniel Buchholz
- Gregory ChronowskiGCGregory Chronowski
- Tomas DvorakTDTomas Dvorak
- Emily GradeEGEmily Grade
- Karen HoffmanKHKaren Hoffman
- George PerkinsGPGeorge Perkins
- 10 December 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (35) , 3495-3503
Abstract
Purpose: The adoption of hypofractionated whole-breast irradiation (HF-WBI) remains low, in part because of concerns regarding its safety when used with a tumor bed boost or in patients who have received chemotherapy or have large breast size. To address this, we conducted a randomized, multicenter trial to compare conventionally fractionated whole-breast irradiation (CF-WBI; 50 Gy/25 fx + 10 to 14 Gy/5 to 7 fx) with HF-WBI (42.56 Gy/16 fx + 10 to 12.5 Gy/4 to 5 fx). Patients and Methods: From 2011 to 2014, 287 women with stage 0 to II breast cancer were randomly assigned to CF-WBI or HF-WBI, stratified by chemotherapy, margin status, cosmesis, and breast size. The trial was designed to test the hypothesis that HF-WBI is not inferior to CF-WBI with regard to the proportion of patients with adverse cosmetic outcome 3 years after radiation, assessed using the Breast Cancer Treatment Outcomes Scale. Secondary outcomes included photographically assessed cosmesis scored by a three-physician panel and local recurrence-free survival. Analyses were intention to treat. Results: A total of 286 patients received the protocol-specified radiation dose, 30% received chemotherapy, and 36.9% had large breast size. Baseline characteristics were well balanced. Median follow-up was 4.1 years. Three-year adverse cosmetic outcome was 5.4% lower with HF-WBI ( Pnoninferiority = .002; absolute risks were 8.2% [n = 8] with HF-WBI v 13.6% [n = 15] with CF-WBI). For those treated with chemotherapy, adverse cosmetic outcome was higher by 4.1% (90% upper confidence limit, 15.0%) with HF-WBI than with CF-WBI; for large breast size, adverse cosmetic outcome was 18.6% lower (90% upper confidence limit, −8.0%) with HF-WBI. Poor or fair photographically assessed cosmesis was noted in 28.8% of CF-WBI patients and 35.4% of HF-WBI patients ( P = .31). Three-year local recurrence-free survival was 99% with both HF-WBI and CF-WBI ( P = .37). Conclusion: Three years after WBI followed by a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar. Tumor bed boost, chemotherapy, and larger breast size do not seem to be strong contraindications to HF-WBI.Keywords
This publication has 27 references indexed in Scilit:
- Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized TrialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Choosing Wisely? Patterns and Correlates of the Use of Hypofractionated Whole-Breast Radiation Therapy in the State of MichiganInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Long-term Outcomes of Hypofractionation Versus Conventional Radiation Therapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ of the BreastInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case seriesMedical Oncology, 2014
- Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation TherapyJournal of Clinical Oncology, 2013
- The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsThe Lancet Oncology, 2013
- Accelerated fractionation with a concurrent boost for early stage breast cancerRadiotherapy and Oncology, 2013
- Fractionation for Whole Breast Irradiation: An American Society for Radiation Oncology (ASTRO) Evidence-Based GuidelineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Long-Term Results of Hypofractionated Radiation Therapy for Breast CancerNew England Journal of Medicine, 2010
- Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trialThe Lancet Oncology, 2006